Samsung Biologics and AstraZeneca to Dissolve Rituximab Alliance
AstraZeneca Presents Results of Imfinzi (durvalumab) + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV NSCLC at WCLC 2021
Shots:
- Samsung Biologics and AstraZeneca had decided to suspend long-running research and development activities by a jointly-owned subsidiary, Archigen Biotech, which was solely engaged in the development of SAIT101 (biosimilar, rituximab)
- Samsung halted the P-III study of SAIT101 in Oct’2012 and resumed it in 2014 via Archigen. The P-III study similar therapeutic effect to Rituxan in 315 FL patients with ORR (66.3% vs 70.6%)
- The companies decided to stop commercializing SAIT101 and take a step for liquidation of Archigen as the product lacks commercial viability
Source 1, Source 2 to read full press release/ article | Ref: Centerforbiosimilars, Korean Biomed | Image: New Europe